Archive for December, 2015

(RIBT) & Kentucky Equine Research Sign Exclusive Supply & Cooperation Agreement

World Leader in Equine Nutrition Partners with Technology Leader in Rice Bran Stabilization and Processing

SCOTTSDALE, Arizona, December 30, 2015  —

RiceBran Technologies (NASDAQ: RIBT and RIBTW) (the “Company” or “RBT”), a global leader in the production and marketing of value added products derived from rice bran, today announced that the Company has entered into a 10 year Exclusive Supply and Cooperation Agreement covering the North American equine market with Kentucky Equine Research (“KER”), an international equine nutrition, research, and consultation company serving horse owners and the feed industry.

Under the terms of the agreement, RBT will be the exclusive supplier of stabilized rice bran (“SRB”) endorsed by KER for use as a feed and supplement ingredient in equine products sold in North America. RBT will provide manufacturing, distribution, sales and marketing expertise and KER will contribute sales and marketing expertise, technical support and research and development to the partnership.

Dr. Joe Pagan, President and Founder of KER, commented: “We are excited to enter into this agreement with RiceBran Technologies. In addition to RBT being the technology leader in rice bran stabilization, their patented processes produce a range of unique rice bran derivatives that we will jointly develop with the aim of producing high value equine supplements with targeted nutritional applications.”

W. John Short, CEO & President of RBT, commented: “Dr. Pagan has built KER into the leading equine nutrition company in the world.  It is a pleasure and an honor to have the opportunity to cooperate with Joe and KER to increase market penetration for both of our companies as we work to bring new, high value equine feeds and supplements to the North American equine market.”

About Kentucky Equine Research

Kentucky Equine Research (KER) is an international equine nutrition, research, and consultation company serving horse owners and the feed industry.  KER’s goals are to advance the industry’s knowledge of equine nutrition and exercise physiology, apply that knowledge to produce healthier, more athletic horses, and support the nutritional care of all horses throughout their lives.  For more information about KER, please visit https://ker.com .

About RiceBran Technologies

RiceBran Technologies is a human food ingredient and animal nutrition company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. RiceBran Technologies has proprietary and patented intellectual property that allows us to convert rice bran, one of the world’s most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products.  Our target markets are human food ingredients and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutritional supplement manufacturers and retailers, both domestically and internationally. More information can be found in the Company’s filings with the SEC and by visiting our website at http://www.ricebrantech.com .

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements about RiceBran Technologies’ expectations regarding recovery of funds from an escrow account related to the 2008 purchase of Irgovel. These statements are made based upon current expectations that are subject to known and unknown risks and uncertainties.  RiceBran Technologies does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.  Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in this press release and in RiceBran Technologies’ filings with the Securities and Exchange Commission, including its most recent periodic reports.

Investor Contact:
Ascendant Partners, LLC
Fred Sommer
+1-732-410-9810
fred@ascendantpartnersllc.com

Wednesday, December 30th, 2015 Uncategorized Comments Off on (RIBT) & Kentucky Equine Research Sign Exclusive Supply & Cooperation Agreement

(MTP) Completes Acquisition of (GALE) Zuplenz®

Further Product Acquisition Bolsters Marketed Oncology Portfolio

OXFORDSHIRE, United Kingdom, Dec. 30, 2015  — Midatech Pharma (“Midatech” or the “Company” or the “Group”) (AIM:MTPH) (Nasdaq:MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology and other therapeutic areas, today announces the successful completion of its previously announced acquisition of Zuplenz® (ondansetron), a marketed oncology product from Galena Biopharma, Inc. (NASDAQ:GALE). Zuplenz® is marketed in the US for the prevention of chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) and has a target market of $4.6bn by 2018.

As announced on 18 December 2015, Midatech expects the acquisition of Zuplenz® will leverage its commercial infrastructure in the US, following the recent acquisition of DARA BioSciences (now known as Midatech Pharma US Inc.).

Commenting on the announcement, Dr. Jim Phillips, CEO of Midatech Pharma, said: “We are pleased to complete the acquisition of Zuplenz®, which adds to our rapidly growing portfolio of marketed oncology products. We believe that our recent product acquisitions will help drive the Group towards sustainable profitability.”

References:

Antiemetic Drugs: World Industry and Market Analysis 2014-2024

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech’s strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company’s R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

About Zuplenz®

Zuplenz® was launched in the US in July 2015 and is an anti-emetic oral soluble film, which does not need to be injected or swallowed, offering patients a differentiated alternative to other treatments. Zuplenz® complements Midatech’s existing marketed oncology product portfolio and has patent protection until at least 2029. Zuplenz® is targeting an estimated $4.6bn market by 2018 and is expected to add to Midatech’s growing revenues.

Forward Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the anticipated benefits of the acquisition of Zuplenz®, our expected revenues, market and growth opportunities and other benefits associated with the acquisition of Zuplenz® and other statements that are not historical fact. Any forward-looking statements are based on currently available competitive, financial and economic data together with management’s views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements, including but not limited to, operational challenges in achieving our objectives with respect to Zuplenz®, achieving strategic objectives and executing plans, the risk that markets do not evolve as anticipated, the potential impact of the general economic conditions and competition in the industry.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies (“AIM Rules”), the Disclosure and Transparency Rules (“DTRs”) and the rules and regulations promulgated by the US Securities and Exchange Commission (“SEC”), which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising

For more information, please contact:

Midatech Pharma PLC
Jim Phillips, CEO
Tel: +44 (0)1235 841575
www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)
Corporate Finance
Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith
Broking
Tom Salvesen
Tel: +44 (0)20 7886 2500

RBC Europe Limited (Joint Broker)
Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman 
Tel: +44 (0)207 653 4000

Consilium Strategic Communications (Financial PR)
Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys
Tel: +44 (0)20 3709 5700
Email: midatech@consilium-comms.com
Wednesday, December 30th, 2015 Uncategorized Comments Off on (MTP) Completes Acquisition of (GALE) Zuplenz®

(TGEN) Forms JV for Ultera™ Emissions Control Technology

Announces Sale of $3M in Additional Shares

WALTHAM, Mass., Dec. 30, 2015  — Tecogen® Inc. (NASDAQ: TGEN), a manufacturer and installer of high efficiency, ultra-clean combined heat and power products including natural gas engine-driven cogeneration, air conditioning systems, and high-efficiency water heaters for industrial and commercial use, is pleased to announce the formation of a joint venture (“JV”) company with a group of Strategic Investors for its patented Ultera™ emissions control technology. Ultra Emissions Technologies Ltd. (“Ultratek”) was created to advance Tecogen’s near-zero emissions technology for adaptation to transportation applications powered by spark-ignited engines (including gasoline, natural gas, and propane fueled vehicles) in the automobile and truck categories. Tecogen has granted Ultratek an exclusive license for development of its patented, emissions-related, intellectual property for the vehicle market while the Strategic Investors have collectively contributed $3 million to finance the initial operations of the joint venture. Tecogen retains the rights to its Ultera emissions control technology for all other applications.

Robert Panora, Tecogen’s President, Chief Operating Officer, and one of the inventors of the Ultera technology will serve as JV co-Chief Executive Officer alongside Dr. Elias Samaras. Dr. Samaras is the founder, President and Managing Director of Digital Security Technologies S.A. and the Chief Executive Officer of EuroSite Power Inc. In addition to serving as co-CEO of Ultratek, Dr. Samaras has also been named Chairman of the Board of Directors.  The 50/50 joint venture company is incorporated in the Island of Jersey, Channel Islands.

“Our emissions technology systems have been installed and successfully operating for both natural gas and biogas-fueled stationary engine applications for several years now,” said Mr. Panora. “The Emissions Advisory Committee (the formation of which was previously announced in October) believes the system may be successfully applied to automotive engines and we are excited to move forward with our new Strategic Partners to pursue the vast potential vehicle market opportunity.”

Speaking on behalf of Ultratek and its partners, Dr. Samaras added, “We are incredibly enthusiastic about the potential for this technology to revolutionize the automotive market. With stricter emissions regulations taking effect in the next few years, I believe we are at the forefront of the evolving emissions control space.”

The patented ultra-clean emissions control technology has been rigorously tested by independent labs and shown to consistently reduce the emission of criteria pollutants contributing to smog (CO and NOx) to near zero levels for natural gas engines. Tecogen’s emissions technology, developed with funding from the California Energy Commission and Southern California Gas Company, has been independently verified by New Jersey’s Department of Environmental Protection and by AVL California Technology Center. Emissions measurements from stationary systems equipped with the ultra-low emissions technology conform to the current California Air Resource Board (CARB) 2007 carbon monoxide (CO) and nitrogen oxide (NOx) standards for distributed power generation. Engines retrofitted with Tecogen’s Ultera technology measure at or below current natural gas powered fuel cell emissions levels (according to publicly available data). Because of the Company’s strong belief in the value of its emissions technology, patent infringement insurance has been secured by Lloyds of London to defend unlicensed use of Tecogen’s intellectual property.

In addition to the joint venture agreement financing, the Strategic Investors have collectively purchased 890,208 shares in Tecogen at a trailing 30 day average price of $3.37, bringing their total initial investment to $6 million.

Tecogen and its joint venture partners will host a conference call on Tuesday January 5, 2016 at 11:00 AM EST to discuss the transaction.  In addition to a discussion of the JV details, members of senior management will discuss the progress of the Emissions Advisory Committee and other initiatives related to bringing the groundbreaking patented Ultera™ emissions control technology to the automotive space.

The conference call will be available live via telephone and webcast. To listen to the audio portion, dial (888) 349-0103 within the U.S., (855) 669-9657 from Canada, or (412) 902-0129 from other international locations. Participants should ask to be joined to the Tecogen Inc. Emissions JV call. Please begin dialing at least 10 minutes before the scheduled starting time.  Alternately, to register for and listen to the webcast, go to http://investors.tecogen.com/webcast. Supplemental conference call slides will be available on the Company website at http://investors.tecogen.com in the “Webcasts” portion of the Investor Relations section.

The emissions update conference call will be recorded and available for playback one hour after the end of the call through Tuesday, January 12th.  To listen to the playback, dial (877) 344 7529 within the U.S., (855) 669-9658 from Canada, or (412) 317-0088 outside the U.S. and use Conference Number 10078325. Following the call, the webcast will be archived for 30 days.

About Tecogen
Tecogen manufactures, installs, and maintains high efficiency, ultra-clean, combined heat and power products including natural gas engine-driven cogeneration, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company is known for cost efficient, environmentally friendly and reliable products for energy production that, through patented technology, nearly eliminate criteria pollutants and significantly reduce a customer’s carbon footprint.

In business for over 20 years, Tecogen has shipped more than 2,300 units, supported by an established network of engineering, sales, and service personnel across the United States. For more information, please visit www.tecogen.com.

Forward Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Important factors could cause actual results to differ materially from those indicated by such forward-looking statements, as disclosed on the Company’s website and in Securities and Exchange Commission filings. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Tecogen Investor Relations & Media Contact Information:
Ariel F. Babcock, CFA
P: (781) 466-6413
E: Ariel.Babcock@tecogen.com

John N. Hatsopoulos
P: (781) 622-1120
E: John.Hatsopoulos@tecogen.com

Wednesday, December 30th, 2015 Uncategorized Comments Off on (TGEN) Forms JV for Ultera™ Emissions Control Technology

(HART) to Webcast Biotech Showcase™ Presentation Monday, Jan. 11

SAN FRANCISCO and HOLLISTON, Mass., Dec. 30, 2015  — Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that its CEO Jim McGorry will present at the 8th annual Biotech Showcase conference on Monday, January 11th at 2:00 pm. Pacific Time.  Mr. McGorry, Dr. Saverio La Francesca, HART’s Chief Medical Officer, and Tom McNaughton, HART’s CFO, will also be available for investment community meetings in San Francisco Monday, January 11th through Wednesday, January 13th – contact investor relations (below) to schedule a meeting.

HART’s presentation audio and slides will be webcast live and available for replay. The conference will be held at the Parc 55 Hotel in San Francisco, CA.

Live Webcast/Replay:   http://edge.media-server.com/m/p/dfrf568n

About Biotech Showcase™ (http://www.ebdgroup.com/bts/index.php)
Biotech Showcase™ is an investor and networking conference providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and industry executives in one place during the course of one of the largest annual gatherings of healthcare investors. Now in its eighth year, Biotech Showcase 2016 is expected to attract upwards of 2,100 attendees.

About HART (http://www.harvardapparatusregen.com)
Harvard Apparatus Regenerative Technology (HART) makes bioengineered implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the trachea and bronchus airways. Our first generation tracheal implant has been used successfully in five adult human implant procedures approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority. HART is completing further large-animal studies to refine our technology platform with the goals of pursuing one or more compassionate use implantation surgeries and filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates.

Twitter:  Investor Relations @HART_IR_Team
StockTwits: @HART_Investor_Relations

Investor Relations:

Harvard Apparatus Regenerative Technology, Inc.
Tom McNaughton
Chief Financial Officer
774-233-7321

Catalyst Global LLC
David Collins, Tanya Kamatu
212-924-9800
hart@catalyst-ir.com

Wednesday, December 30th, 2015 Uncategorized Comments Off on (HART) to Webcast Biotech Showcase™ Presentation Monday, Jan. 11

(VUZI) adds Atheer AiR™ Suite for Remote Expert Collaboration and Rapid Task Flow Deployment

Vuzix M100 enabled with the AiR Suite augmented reality application allows field workers and other deskless professionals real-time communication

ROCHESTER, N.Y., Dec. 30, 2015  — Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of video eyewear and smart glasses products in the consumer, enterprise and entertainment markets, is pleased to announce that the company has formed a partnership with Atheer, a pioneer of AiR™ (Augmented interactive Reality) computing. The Vuzix M100 Smart Glasses now supports Atheer’s AiR Suite designed specifically for remote expert collaboration, management and rapid task flow deployment, which can be downloaded from the Vuzix app store.

“The M100 Smart Glasses can enhance workflows for companies in a broad range of sectors,” said Paul Travers, President and Chief Executive Officer of Vuzix. “Atheer’s AiR suite is well aligned with the enterprise class productivity and collaboration capabilities that our customers expect from our devices. We’re looking forward to an ongoing relationship that will benefit both of our companies to provide a world-class enterprise solution.”

“We’re excited to work with Vuzix, as their hardware complements and works seamlessly with our AiR Suite for Enterprise,” said Alberto Torres, CEO of Atheer. “The deskless workforce in Fortune 1000 entities is growing rapidly and needs hands-free access to task-specific information, as well as real-time guidance for complex tasks. Our AiR Suite software and Vuzix M100 is a fitting combination for companies looking to maximize performance and deploy smart glasses-based productivity, immediately.”

Communication between deskless professionals and subject matter experts is key to enabling quick decision making and a productive workforce. The M100 with the Atheer AiR suite enables deskless professionals to see checklists and step-by-step procedures in their smart glasses and enjoy hands-free interaction with information using simple gestures, voice, or head motion. Further, the suite enables professionals to team up with remote experts via video calls and receive guidance through real-time image annotations to resolve problems quickly. The AiR Suite also includes an intuitive task flow authoring tool that allows enterprises to create smart glasses-optimized procedures and task flows with a simple drag-and-drop interface, saving valuable R&D resources and months of development time.

Vuzix and Atheer will demonstrate the AiR Suite running on M100 Smart Glasses in the Vuzix booth #14048 at the Consumer Electronics Show on January 6-9th in Las Vegas. More information about the Vuzix M100 can be found here and about the Atheer AiR Suite here. The AiR Suite is available for download at the Vuzix App Store and the full subscription license is priced at $49 per user per month. All Vuzix customers, however, will receive a 30 day free trial.

About Atheer

Atheer is the pioneer of AiR™ (Augmented interactive Reality) computing that is designed to enhance the productivity and safety of deskless professionals at Fortune 1000 companies. The award-winning Atheer AiR platform combines the power of immersive augmented reality with intelligent gesture, voice and head-motion interactions as well as real-time rich-media collaboration, all on a mobile smart glasses platform. Wearing the see-through AiR Glasses enables viewing rich information critical to workflows, interacting with the information naturally and collaborating with remote peers like never before – without the need to hold any device. Leveraging the Android-based AiR OS and the collaboration-centric AiR Suite, developers and companies around the world are creating next generation enterprise productivity applications and workflows to empower the 21st century workforce. The company is based in Mountain View, CA and is backed by prominent investors including Bobby Yazdani, Founder and Managing Partner of Cota Capital and Signatures Capital, and Farzad Naimi, Co-Founder & Managing Partner, RONA Holdings. For more information, please visit http://www.atheerair.com, follow us on Twitter and LinkedIn, and like us on Facebook.

About Vuzix Corporation

Vuzix is a leading supplier of Video Eyewear and Smart Glasses products in the consumer, commercial and entertainment markets. The Company’s products include personal display and wearable computing devices that offer users a portable high quality viewing experience, provide solutions for mobility, wearable displays and virtual and augmented reality. Vuzix holds 41 patents and 12 additional patents pending and numerous IP licenses in the Video Eyewear field. The Company has won Consumer Electronics Show (or CES) awards for innovation for the years 2005 to 2015 and several wireless technology innovation awards among others. Founded in 1997, Vuzix is a public company (NASDAQ: VUZI) with offices in Greater Rochester, NY, Oxford, UK and Tokyo, Japan.

Forward-Looking Statements Disclaimer

Certain statements contained in this news release are “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward looking statements contained in this release relate to the success of Atheer partnership, their products use with the M100 Smart Glasses, and customer sales, and among other things the Company’s leadership in the Video Eyewear, VR and AR display industry. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and MD&A filed with the United States Securities and Exchange Commission and applicable Canadian securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

For further information:

Media and Investor Relations Contact:

Andrew Haag
Managing Partner
IRTH Communications
vuzi@irthcommunications.com
Tel: (866) 976-4784

Vuzix Corporation
25 Hendrix Road, Suite A
West Henrietta, NY 14586 USA
Investor Information – Grant Russell
IR@Vuzix.com
Tel: (585) 359-7562
www.vuzix.com

Atheer Contact:
Monica Cho
monica.cho@sparkpr.com
(415) 685-4273

For further sales, and product information, please visit:

North America:
http://www.vuzix.com/contact/

Europe/UK:
http://www.vuzix.eu/contact/

Asia:
http://www.vuzix.jp/contact.html

Wednesday, December 30th, 2015 Uncategorized Comments Off on (VUZI) adds Atheer AiR™ Suite for Remote Expert Collaboration and Rapid Task Flow Deployment

(OHGI) China Mobile VoIP Telco Subsidiary Doubles Revenues 3rd Quarter In A Row

Aishuo App Surpasses 12 Million Downloads, China System Upgrade Scheduled for Immediate Deployment to Handle Demand

LIMERICK, IRELAND–(Dec 30, 2015) – One Horizon Group, Inc. (NASDAQ: OHGI), a leading carrier-grade VoIP solution for mobile providers and smartphones, announced today it has upgraded its China mobile VoIP telco Aishuo™ (“Aishuo”) to allow the purchase of communication-stickers. The decision to expand the commercial offering in China was made due to the overwhelming growth of Aishuo with over 12 million downloads in the last 9 months, putting the company growth trajectory 18 months ahead of its forecasted targets to acquire 15 million app subscribers over a two-year period. As a result, Aishuo revenues have increased for a 3rd consecutive 100% growth quarter accelerating the monetization strategy.

Aishuo communication-stickers are a mix of cartoons and smiley-like emojis. This mix gives our users an addictive new way to communicate emotions and feelings with quirkiness. Using stickers is not only about being expressive, but saves users time over tapping out words on a phone, making communications easier and more rapid; particularly given that Chinese Hanzi is tricky to input digitally. Significant revenues have been seen in the sales of stickers in other social media and mobile apps around the world. The Company believes that industry standard revenues can be achieved with this new sticker feature-set for Aishuo.

One Horizon Group CEO, Brian Collins, noted, “Our deployment in China has exceeded all our internal forecasts and roll-out modeling. Now we’re pushing even further across the Chinese social media market with the addition of the massively popular sticker communication feature. Some stickers will be free of charge while others will have a small payment attached for those special expressions that our mobile subscribers may wish to share.”

Aishuo is available as a FREE download in over 25 App stores including Apple iTunes, Baidu 91.com and Baidu.com, the Tencent App store MyApp.com, 360 Qihoo store 360.cn and Xiaomi on mi.com. Aishuo supports all major Chinese mobile payment platforms including China UnionPay, Apple In-App Purchases, Alibaba’s Alipay and Tencent’s Wechat Wallet providing subscribers with convenient options to purchase call and sticker credit.

About One Horizon Group, Inc.
One Horizon Group Inc.’s business is to optimize communications over the Internet through its wholly owned subsidiary, Horizon Globex GmbH, Zug, which develops and markets one of the world’s most bandwidth-efficient mobile voice over Internet Protocol (VoIP) platforms for smartphones, and also offers a range of other optimized data Applications including messaging and mobile advertising. The company controls and operates the Aishuo mobile VoIP service in China. Horizon Globex GmbH is an ISO 9001 and ISO 20000-1 certified company. The Company has operations in Ireland, Switzerland, the United Kingdom, China, India, Singapore, Hong Kong and Latin America. For more information on the Company, its products and services, please visit http://www.onehorizongroup.com.

Safe Harbor Statement
This news release may contain “forward-looking” statements. These forward-looking statements are only predictions and are subject to certain risks, uncertainties and assumptions that could cause actual results to differ from those in the forward looking-statements. Potential risks and uncertainties include such factors as uncertainty of consumer demand for the Company’s products, as well as additional risks and uncertainties that are identified and described in Company’s SEC reports. Actual results may differ materially from the forward-looking statements in this press release. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company does not undertake, and it specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement.

Contact:
PR/Media Contact
Matthew Bird
President
1-800-PublicRelations, Inc.
Direct: 646.401.4499
Main: 800.782.6185
Email: matt.bird@1800pr.com

Wednesday, December 30th, 2015 Uncategorized Comments Off on (OHGI) China Mobile VoIP Telco Subsidiary Doubles Revenues 3rd Quarter In A Row

(HDP) Two Major New Big Data Contract Wins for Its Flagship Fusion Product

Major US Financial Services Firm and Global Telecommunications Leader Now Use WANdisco Fusion for Continuous Hadoop Availability, Scalability and Performance

SAN RAMON, CA–(December 29, 2015) – WANdisco (LSE: WAND) a leading provider of continuous availability software for global enterprises to meet the challenges of Big Data, today announced two of the largest deals ever for its flagship Fusion product for Hadoop, with a combined value of well over one million dollars. These two new contracts comprise an initial sale to a well-known US financial services firm, and a major expansion deal with an existing customer that is also one of Europe’s largest mobile carriers. Both customers use Fusion to meet stringent SLAs (service level agreements) for their production business applications deployed on Hadoop.

The financial services customer, one of the largest life insurers in the US, faces stringent regulatory and business requirements for guaranteed data consistency and availability across multiple data centers. Without a large IT staff dedicated to Hadoop support, they also required a solution that was easy to administer with automated disaster recovery to eliminate downtime and data loss. After extensive evaluation, they selected WANdisco Fusion over the backup and recovery solutions offered by the leading Hadoop distribution vendors, as well as those from several major hardware vendors that not only couldn’t match its capabilities, but also came with much greater cost and complexity.

The telecommunications customer, one of Europe’s leading mobile carriers, initially selected WANdisco’s big data technology for continuous availability in 2013 after moving to Hadoop to streamline their service activation system, previously spread across multiple applications and databases. Recently, they expanded the system to new data centers and migrated to a new Hadoop distribution, leveraging Fusion to avoid the downtime and business disruption these activities normally entail. After migration, they found WANdisco Fusion’s platform independent architecture and ability to scale enabled it to work seamlessly in their new environment.

“These customers operate in regulatory and business settings with the most demanding SLAs for availability, scalability and performance,” said David Richards, CEO and co-founder at WANdisco. “They also want flexible, future-proof solutions that impose minimal administrative overhead and avoid vendor lock-in, given the dynamic nature of the Hadoop market. Their decision to purchase after extensive evaluation is further proof that WANdisco Fusion is the only solution available that not only meets, but exceeds large enterprise requirements for moving Hadoop from the lab into full-scale production.”

Both companies appreciate WANdisco Fusion’s flexible, easy-to-deploy architecture that eliminates Hadoop downtime and data loss, and enables them to avoid Hadoop vendor lock-in. WANdisco Fusion can be implemented across mixed storage environments, including Oracle BDA, IBM Big Insights (NYSE: IBM), Cloudera, Hortonworks (NASDAQ: HDP), EMC (NYSE: EMC) and MapR. WANdisco recently announced Fusion support for replication to the most widely used cloud storage platforms for migration to cloud, hybrid burst to cloud and streaming backup without downtime or disruption. With all platforms, the functionality is the same.

About WANdisco

WANdisco (LSE: WAND) is a provider of enterprise-ready, non-stop software solutions that enable globally distributed organizations to meet today’s data challenges of secure storage, scalability and availability. WANdisco’s products are differentiated by the company’s patented, active-active data replication technology, serving crucial high availability (HA) requirements, including Hadoop Big Data and Application Lifecycle Management (ALM), including Apache Subversion and Git. Fortune Global 1000 companies, including Juniper Networks, Motorola, and Halliburton, rely on WANdisco for performance, reliability, security and availability. For additional information, please visit http://www.wandisco.com.

Apache Hadoop and Subversion are trademarks of the Apache Software Foundation (ASF). All other product and company names herein may be trademarks of their registered owners.

Contact:
Mackensie Gibson
WANdisco
Email contact
925-365-0289

Megan Nemeh
SHIFT Communications
Email contact
415-591-8409

Tuesday, December 29th, 2015 Uncategorized Comments Off on (HDP) Two Major New Big Data Contract Wins for Its Flagship Fusion Product

(LRAD) Receives $710,000 Latin American Prison Security Order

SAN DIEGO, CALIF., Dec. 29, 2015  — LRAD Corporation (NASDAQ:LRAD), the world’s leading provider of Long Range Acoustic Devices® and advanced ONE VOICE® mass notification systems, today announced it has received a $710,000 LRAD 1000Xi systems and accessories order for prison security in Latin America.

“LRAD systems fundamentally change the way corrections officers secure prisons, facility perimeters and conduct many operations,” commented Tom Brown, President and Chief Executive Officer of LRAD Corporation. “As an instant force multiplier, LRAD frees officers to prevent dangerous situations from escalating.”

The superior voice intelligibility and extended frequency range of the LRAD 1000Xi safely alters behavior, disperses inmates, facilitates cell extractions, establishes standoff zones between guards and prisoners, disrupts prisoner communication, alleviates the escalation of force during fights, riots, hostage and barricaded subject situations, and quickly resolves uncertain situations to prevent injuries and save lives.

About LRAD Corporation

LRAD Corporation designs, manufactures and markets Long Range Acoustic Devices® and advanced ONE VOICE® mass notification systems to save lives. LRAD systems are in service in more than 70 countries around the world in diverse applications including mass notification and public address, fixed and mobile defense deployments, maritime security, critical infrastructure and perimeter security, commercial security, border and port security, law enforcement and emergency responder communications, asset protection, and wildlife control and preservation. For more information, please visit www.lradx.com.

Forward Looking Statements

Except for historical information contained herein, the matters discussed are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on these statements. We base these statements on particular assumptions that we have made in light of our industry experience, the stage of product and market development as well as our perception of historical trends, current market conditions, current economic data, expected future developments and other factors that we believe are appropriate under the circumstances. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward-looking statements. These risks and uncertainties are identified and discussed in our filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management’s expectations as of the date hereof. Future results may differ materially from our current expectations. For more information regarding other potential risks and uncertainties, see the “Risk Factors” section of the Company’s Form 10-K for the fiscal year ended September 30, 2015. LRAD Corporation disclaims any intent or obligation to update those forward-looking statements, except as otherwise specifically stated.

CONTACT: E. Brian Harvey
         Director, Investor Relations and Capital Markets
         858.753.8974 
         ebharvey@lradx.com
Tuesday, December 29th, 2015 Uncategorized Comments Off on (LRAD) Receives $710,000 Latin American Prison Security Order

(NERV) Announces Update on MIN-101 Clinical Development Program

Enrollment Completed in European Phase IIb Trial and Investigational New Drug (IND) Application Accepted by U.S. FDA

WALTHAM, Mass., Dec. 29, 2015  — Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application for MIN-101, a first-in-class 5-HT2a and sigma2 antagonist in clinical development for the treatment of schizophrenia.

In addition, the Company announced the completion of the enrollment of a total of 244 patients in a randomized, placebo-controlled double-blind European Phase IIb clinical trial of MIN-101. The primary objective of this trial is to evaluate the efficacy of MIN-101 compared to placebo in improving the negative symptoms of schizophrenic patients.  Additional objectives include the assessment of cognitive symptoms and overall symptomatology of the disease following treatment with MIN-101.   Topline results from the core 12-week treatment evaluation period are expected in the second quarter of 2016.

“Acceptance of the IND for MIN-101 is an important step toward the initiation of advanced-stage clinical testing of this compound in the U.S. following the results of our ongoing Phase IIb trial in Europe,” said Remy Luthringer, president and chief executive officer of Minerva.  “We will be continuing our dialogue with the FDA as part of our overall planning for late-stage clinical testing in the U.S.”

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases.  Minerva’s proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), in Phase IIa and Phase Ib development for insomnia and the adjunctive treatment of major depressive disorder (MDD), respectively; MIN-117, in development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended.  Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties.  Forward-looking statements include statements herein with respect to the timing and results of future clinical milestones with MIN-101; the clinical and therapeutic potential of MIN-101; our ability to successfully develop and commercialize MIN-101; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals.  These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether MIN-101 will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether MIN-101 will be successfully marketed if approved; whether our therapeutic product discovery and development efforts with MIN-101 will be successful; our ability to achieve the results contemplated by our co-development agreements; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions.  These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the Securities and Exchange Commission on November 5, 2015. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

 

Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
Tuesday, December 29th, 2015 Uncategorized Comments Off on (NERV) Announces Update on MIN-101 Clinical Development Program

(VTAE) Doses First Patients in Phase 2a Proof-of-Concept of VTP-38543

Top-Line Results Expected in the Second Half of 2016

FORT WASHINGTON, Pa., Dec. 29, 2015  — Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has dosed the first patients in its Phase 2a proof-of-concept clinical trial of VTP-38543 in atopic dermatitis (AD). VTP-38543 is the Company’s topical LXRβ selective agonist for the treatment of AD, a skin condition characterized by an intense itch / scratch cycle and driven by both inflammation and a breakdown of the skin’s barrier function.

Earlier this month, Vitae announced plans to initiate this four-week, randomized, double-blind Phase 2a trial, which will assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple ascending topical doses of VTP-38543 in approximately 100 adult patients with mild to moderate AD. The Company expects to report top-line results in the second half of 2016.

“Dosing the first patients in this trial brings us closer to gauging VTP-38543’s potential to become a novel therapeutic approach to manage the needs of atopic dermatitis patients, many of which we believe are not being met by currently marketed treatments,” said Dr. Richard Gregg, Chief Scientific Officer of Vitae.

About Atopic Dermatitis

Atopic dermatitis (AD) is a skin condition affecting approximately 17.5 million infants, adolescents and adults in the U.S. It is characterized by intense itching and is caused by both inflammation and a breakdown of the skin’s barrier function. Activation of LXR in skin keratinocytes, the most common cell type in the outer layer of skin, has been shown to increase the formation of corneocytes and the production of lamellar lipids (the ‘bricks and mortar’ of the outer layer of skin). LXR activation also has been shown to have an anti-inflammatory effect in skin equivalent to a high potency corticosteroid. Vitae believes that increasing LXR activity with VTP-38543 may be beneficial for AD patients by both decreasing skin inflammation and repairing the damaged outer layer of skin.

About VTP-38543

VTP-38543 is Vitae’s LXRβ selective agonist with the potential to significantly impact the treatment of atopic dermatitis (AD), a common inflammatory skin disease. In preclinical studies, VTP-38543 was shown to increase LXR activity, decrease skin inflammation, and increase the production and secretion of lipids necessary for maintaining the barrier function, resulting in a potentially superior therapy for AD. In December 2015, Vitae initiated a Phase 2a proof-of-concept clinical trial in patients with mild to moderate AD.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae’s lead clinical assets include VTP-43742, an oral RORyt inhibitor currently being studied in patients with moderate to severe psoriasis, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.

For additional information, please visit the company’s website at www.vitaepharma.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the clinical development of VTP-38543. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan,” “impending” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward- looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vitae is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vitae’s forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Vitae and its collaborative partners; the ability to obtain and maintain regulatory approval of Vitae’s product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Vitae’s product candidates; the size and growth of the potential markets for Vitae’s product candidates and the ability to serve those markets; Vitae’s expectations regarding Vitae’s expenses and revenue, the sufficiency of Vitae’s cash resources and needs for additional financing; Vitae’s ability to attract or retain key personnel; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vitae’s Annual Report on Form 10-K for the year ended December 31, 2014 and Vitae’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 which have been filed with the Securities and Exchange Commission (SEC). In addition to the risks described above and in Vitae’s other filings with the SEC, other unknown or unpredictable factors also could affect Vitae’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vitae undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

 

INVESTORS:
Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
rmorris@vitaerx.com

Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com

MEDIA:
6 Degrees PR
Tony Plohoros
(908) 541-2839
tplohoros@6degreespr.com
Tuesday, December 29th, 2015 Uncategorized Comments Off on (VTAE) Doses First Patients in Phase 2a Proof-of-Concept of VTP-38543

(KRNT) to Present at the 2016 Needham Growth Conference

ROSH-HA`AYIN, Israel, Dec. 29, 2015  — Kornit Digital Ltd. (NASDAQ:KRNT), a company that develops, designs and markets innovative digital printing solutions for the global printed textile industry, today announced that Gabi Seligsohn, the Company’s Chief Executive Officer, and Guy Avidan, the Company’s Chief Financial Officer, will present at the 2016 Needham Growth Conference on Tuesday, January 12, 2016 at 11:20 a.m. ET in New York City.

Mr. Seligsohn and Mr. Avidan will be available January 12 and 13 for one-on-one meetings. To schedule a one-on-one meeting, please contact your Needham sales representative. A live webcast of the presentation will be accessible at ir.kornit.com in the “Events & Presentations” section. Interested parties unable to listen to the live webcast can access an archived version of the webcast on the Company’s website for approximately 90 days.

About Kornit 

Kornit (NASDAQ:KRNT) develops, designs and markets innovative digital printing solutions for the global printed textile industry. Kornit’s solution includes its proprietary digital printing systems, ink and other consumables, associated software and value added services. Kornit’s vision is to revolutionize the textile industry by facilitating the transition from analog processes that have not evolved for decades to digital methods of production that address contemporary supply, demand and environmental dynamics. Kornit is a global company headquartered in Rosh-Ha`Ayin, Israel, with U.S. offices in Mequon, Wisconsin and additional sales, support and marketing offices in Germany and Hong Kong.

 

Investor contact:
Michael Callahan, ICR
(203) 682-8311
Michael.Callahan@icrinc.com
Tuesday, December 29th, 2015 Uncategorized Comments Off on (KRNT) to Present at the 2016 Needham Growth Conference

(SKIS) Closes on $20 Million Line of Credit

WILDWOOD, Mo., Dec. 29, 2015 — Peak Resorts, Inc. (NASDAQ:SKIS), a leading owner and operator of high-quality, individually branded ski resorts in the U.S., today announced it has successfully closed on a $20 million line of credit for acquisition financing with a group of banks led by Royal Banks of Missouri.

Timothy D. Boyd, president and chief executive officer, said, “We expect to close on our previously announced acquisition of Hunter Mountain shortly. We will be financing the cash portion of the transaction with a first mortgage of approximately $20 million secured by Hunter Mountain assets and by drawing approximately $15 million from the line of credit. The line provides us with important flexibility as we implement our roadmap for growth, which calls for a mix of organic growth, resort development and acquisitions. As we have stated, we continue to evaluate potential value-add properties for acquisition.”

The line of credit is for a 12-month period with options to renew any unused portion or convert any outstanding balance to a three-year balloon loan. The interest rate on the line is prime plus 1.0 percent with an annual upfront commitment fee equal to 1.0 percent of the loan amount. The line is secured primarily by Peak Resorts’ currently unencumbered resort assets.

About Peak Resorts

Headquartered in Missouri, Peak Resorts is a leading owner and operator of high-quality, individually branded ski resorts in the U.S. The company currently operates 13 ski resorts primarily located in the Northeast and Midwest, 12 of which are company owned, and recently announced that it has entered into an agreement to purchase Hunter Mountain, the Catskills’ premier winter resort destination.

The majority of the resorts are located within 100 miles of major metropolitan markets, including New York City, Boston, Philadelphia, Cleveland and St. Louis, enabling day and overnight drive accessibility. The resorts under the company’s umbrella offer a breadth of activities, services and amenities, including skiing, snowboarding, terrain parks, tubing, dining, lodging, equipment rentals and sales, ski and snowboard instruction and mountain biking and other summer activities. To learn more, visit the company’s website at PeakResorts.com, or follow Peak Resorts on Facebook (https://www.facebook.com/skipeakresorts) for resort updates.  The company expects all of its resorts, as well as Hunter Mountain, will be open for the New Year’s weekend.

Forward Looking Statements

This press release contains forward-looking statements regarding the future outlook and performance of Peak Resorts, within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from current expectations. These risks and uncertainties include, but are not limited to, risk factors that could affect the company’s ability to consummate the offering and other risks and uncertainties that are contained in its filings with the Securities and Exchange Commission.  Peak Resorts undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

For Further Information:
Heather Wietzel, 616-233-0500
InvestorRelations@PeakResorts.com
Tuesday, December 29th, 2015 Uncategorized Comments Off on (SKIS) Closes on $20 Million Line of Credit

(OVLY) Announces Commercial Credit Officer Hiring

OAKDALE, CA–(Dec 28, 2015) – Oak Valley Community Bank, a wholly owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), recently announced that Edward Vassallo has joined the Bank as Vice President, Commercial Credit Officer. He will be based out of the Bank’s Oakdale headquarters.

Vassallo has over 25 years of commercial banking experience. In his new role, he will be responsible for portfolio management as well as monitoring and maintaining credit quality within the commercial and small business portfolios.

Vassallo holds a Bachelor of Science degree with an emphasis in Finance and Accounting from the University of California, Berkeley. In this free time, he enjoys traveling, exercise, and physical fitness. He currently resides in Stockton.

“We are excited to have Edward join our Credit Administration team. He brings a wealth of commercial credit and underwriting experience to Oak Valley and shares our strong credit quality and relationship banking values,” stated Senior Vice President, Gary Stephens.

Oak Valley Bancorp operates Oak Valley Community Bank & Eastern Sierra Community Bank, through which it offers a variety of loan and deposit products to individuals and small businesses. They currently operate through 16 conveniently located branches: Oakdale, Turlock, Stockton, Patterson, Ripon, Escalon, Manteca, two branches in Sonora, three branches in Modesto, and three branches in their Eastern Sierra Division, which includes Bridgeport, Mammoth Lakes, and Bishop.

The Company recently completed the acquisition of Mother Lode Bank. Branch and operating system conversion is expected to be completed in the second quarter of 2016.

For more information, call 1-866-844-7500 or visit www.ovcb.com.

Contact:
Chris Courtney/Rick McCarty
Phone: (209) 848-BANK (2265)
Toll Free (866) 8447500
www.ovcb.com

Monday, December 28th, 2015 Uncategorized Comments Off on (OVLY) Announces Commercial Credit Officer Hiring

(SPCB) Signs MoU for Cooperation to Build Mobile Money Solution in Latin America

HERZLIYA, Israel, December 28, 2015  —

SuperCom (NASDAQ: SPCB), a global provider of secure solutions for e-Government, Public Safety, HealthCare, and Finance sectors, announced today that it has signed a memorandum of understanding with a Mobile Network Operator in Latin America to implement and deliver a mobile money solution using SuperCom’s SuperPay™ technology.

Both parties expressed their desire to cooperate in building an advanced secure mobile wallet solution to be used by existing subscribers with almost any mobile device and to deploy matching mobile POS technology through the operator’s agent network. The solution is intended to provide a range of services such as cash deposits and withdrawals, money transfer, bill payments, account top ups, in-store payments and more. The business model is based on revenue sharing between the Mobile Network Operator and SuperCom.

SuperPay is SuperCom’s secure mobile payment hybrid suite which brings a new level of secured cross-network mobile payment transaction capabilities. Designed specifically as a flexible end-to-end mobile payments solution, the SuperPay suite is a secure and effective customizable answer for governments, MNOs and banks. Solving major money transfer and payments problems, and considering the unbanked population, SuperPay can be used for depositing, withdrawing and transferring funds and for paying for goods and bills on almost any mobile phone. While supporting multiple payment methods such as mobile-money, credit / debit cards and bank accounts, SuperPay monetary transactions are processed over a tightly-secured closed / open-loop protective layer employing an array of technologies – such as biometric authentication, IVR, and NFC – without additional hardware needed. The SuperPay Suite includes:

  • SuperWallet – an app providing secured financial services on almost any mobile device
  • SuperPOS for secured and audio authenticated Point of Sales payments
  • SafeMoney for safeguarding against device and network-based threats
  • SuperGW – a fully customized payments processing gateway platform
  • PayGuard for secured one-click ecommerce payments with multi-level authentication

 

There is no assurance that the MOU will result in a definite agreement on terms that are acceptable by both parties.

About SuperCom

Since 1988, SuperCom has been a leading global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secured Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers advanced secure mobile payments ranging from mobile wallet to mobile POS using a set of components and platforms to enable secure mobile payments and financial services. SuperCom is a global provider of a unique all-in-one field-proven RFID & mobile PureSecurity advanced solutions suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation.

SuperCom’s website: http://www.supercom.com

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded or followed by or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. Forward-looking statements in this release also include statements about business and economic trends. Investors should also consider the areas of risk described under the heading “Forward Looking Statements” and those factors captioned as “Risk Factors” in the Company’s periodic reports under the Securities Exchange Act of 1934, as amended, or in connection with any forward-looking statements that may be made by the Company. These statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements arising from the annual audit by management and the Company’s independent auditors. The Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Investor Relations Contacts:
Brett Maas / Rob Fink
Hayden IR
+1-646-536.7331 / +1-646-415-8972
spcb@haydenir.com

Company Contact:
Ordan Trabelsi, President, Americas
Tel: +1-212-675-4606
ordan@supercom.com

Monday, December 28th, 2015 Uncategorized Comments Off on (SPCB) Signs MoU for Cooperation to Build Mobile Money Solution in Latin America

(DFRG) Closes Phoenix Del Frisco’s Grille

SOUTHLAKE, Texas, Dec. 28, 2015  — Del Frisco’s Restaurant Group, Inc. (NASDAQ:DFRG) today announced that it has closed the Del Frisco’s Grille located at 2425 E. Camelback Road in Phoenix, AZ, effective December 24, 2015.  The Company will incur one-time lease termination and closing costs related to the Phoenix Del Frisco’s Grille during the fourth quarter.

“Closing our Phoenix Del Frisco’s Grille enables us to focus on other, more profitable restaurants and is therefore in the best interest of our company and shareholders,” said Mark S. Mednansky, CEO of Del Frisco’s Restaurant Group.  “Although this particular restaurant has been challenged for some time, the Grille concept continues to resonate with guests and we look forward to bringing Del Frisco’s Grilles to select locations that are a fit for the brand.”

About Del Frisco’s Restaurant Group, Inc.
Based in Southlake, Texas, near Dallas, Del Frisco’s Restaurant Group, Inc. is a collection of 50 restaurants across 22 states and Washington, D.C., including Del Frisco’s Double Eagle Steak House, Sullivan’s Steakhouse, and Del Frisco’s Grille. Del Frisco’s Double Eagle Steak House serves up flawless cuisine that’s bold and delicious, an extensive award-winning wine list and a level of service that reminds guests that they’re the boss. Sullivan’s Steakhouse is a great neighborhood place for a big night out on the town – with outstanding food, hand-shaken martinis, an award winning wine list, and live entertainment all under one roof. Del Frisco’s Grille is modern, inviting, stylish and fun, taking the classic bar and grill to new heights, and drawing inspiration from bold flavors and market-fresh ingredients.

For further information about our restaurants, to make reservations, or to purchase gift cards, please visit: www.DelFriscos.com, www.SullivansSteakhouse.com, and www.DelFriscosGrille.com. For more information about Del Frisco’s Restaurant Group, Inc., please visit www.DFRG.com.

 

Media Contact:
Christine Beggan
ICR
(203) 682-8329 
christine.beggan@icrinc.com
Monday, December 28th, 2015 Uncategorized Comments Off on (DFRG) Closes Phoenix Del Frisco’s Grille

(PSDV) Plans Medidur™ EU Marketing Approval Application

WATERTOWN, Mass., Dec. 28, 2015  — pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that it plans to file for EU marketing approval of Medidur™ for chronic non-infectious uveitis of the posterior segment of the eye (posterior uveitis) based on data from a single pivotal trial as a result of the high statistical significance achieved in its first Phase 3 clinical trial. The U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) advised pSivida that, consistent with the published Points to Consider (PtC) of the European Agency for Evaluation of Medicinal Products, an application for a product treating a condition like posterior uveitis could be based on statistically compelling and clinically relevant results from just one pivotal trial. The MHRA recently provided this specific advice in formal minutes of a meeting with pSivida held on October 29, 2015 (prior to the Company’s receipt of topline results for its first Phase 3 clinical trial). With those results now available, pSivida plans to confirm with the MHRA the plan to file for EU marketing approval of Medidur based on one trial.

“We are delighted with this advice provided by the MHRA. We expect the high statistical significance of the efficacy data, clinical benefits and positive safety data in our first trial will meet the criteria used by MHRA and other EU regulatory authorities to approve a product on the basis of a single pivotal study,” said Paul Ashton, president and CEO of pSivida Corp. “Using data from a single clinical trial would significantly accelerate our filing for EU marketing approval for Medidur. As posterior uveitis affects a similar number of people in the EU and the U.S., accelerated approval in the important EU market would be very beneficial to us.”

pSivida’s first Phase 3 clinical trial for Medidur for Posterior Uveitis met its primary endpoint of prevention of recurrence of disease at six months with exceptional statistical significance (p < 0.00000001, intent to treat). Exploratory analyses of Medidur-treated eyes compared to control at six months also showed statistical significance: improvement in visual acuity (gain of 15 or more letters on the Early Treatment Diabetic retinopathy Study (ETDRS) Eye Chart) (p = 0.011), reduction in treatment with systemic treatments (steroids, immunosuppressants and biologics) (p < 0.01), and prevention of loss of vision (loss of 15 or more letters) (p < 0.0001). Safety data at six months comparing Medidur-treated eyes to control eyes were also positive, including the observation of modest relative increases in intraocular pressure (IOP) above 21mmHg and cataract surgeries.

Based on the PtC and MHRA minutes, and pending confirmation from the MHRA, pSivida plans to base its EU submission for Medidur for posterior uveitis on safety and efficacy data from the referenced single Phase 3 trial, available safety data from its second Phase 3 trial, data from a short-duration inserter study and data incorporated from ILUVIEN® from DME Phase 3 trials. pSivida expects to file for European approval in the second half of 2016. A U.S. New Drug Application is planned in the first half of 2017 based on results from both of pSivida’s Phase 3 trials.

About Medidur Phase 3 Trials. pSivida is conducting two Phase 3 trials to assess the safety and efficacy of Medidur for the treatment of posterior uveitis. These are randomized, sham injection-controlled, double-masked trials. The primary endpoint of both trials is prevention of recurrence of posterior uveitis at six months, with patients in both trials followed for three years. The first Phase 3 Medidur trial, which enrolled 129 patients in 16 centers in the U.S. and 17 centers outside the U.S, achieved its primary efficacy endpoint with high statistical significance (p < 0.00000001; intent to treat analysis). The second trial, which is still enrolling patients, will enroll up to 150 patients in approximately 15 centers in India. Assuming favorable results from the second Phase 3 trial, an NDA is anticipated in the first half of 2017.  pSivida plans to seek FDA approval of Medidur based on six-month data from the two Phase 3 trials and a short-duration utilization study of pSivida’s redesigned proprietary inserter, together with data referenced from the Phase 3 trials of ILUVIEN for DME.

About Medidur. Medidur is an injectable micro-insert designed to treat posterior uveitis.  Injected into the back of the eye, it provides sustained release of 0.18 mg of the corticosteroid flucinolone acetonide at a controlled rate directly to the retina for three years. Medidur comprises the same micro-insert as ILUVIEN® for DME. ILUVIEN has been approved in the U.S. and 17 EU countries and is sold by pSivida’s licensee in the U.S., U.K., Germany and Portugal.

About Posterior Uveitis. Posterior uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, which is a leading cause of blindness in the developed and developing countries. It afflicts people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. In the U.S., posterior uveitis affects approximately 175,000 people, resulting in approximately 30,000 cases of blindness and making it the third leading cause of blindness in the U.S.

Patients with posterior uveitis are typically treated with systemic steroids, but over time frequently develop serious side effects that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immunosuppressants or biologics, which themselves can have severe side effects, including an increased risk of cancer. Medidur is designed to provide improved outcomes compared to standard of care, but with a significant reduction in side effects.

About pSivida Corp.  pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the U.S. and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida’s lead product candidate, Medidur™, a micro-insert for posterior uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in the first half of 2017. pSivida’s pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida, please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: number of trials and data required for EU marketing application and EU marketing approval; our ability to achieve profitable operations and access to capital; further impairment of our intangible assets; fluctuations in our operating results; declines in Retisert royalties; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of flucinolone acetonide side effects; safety and efficacy results of the second Medidur Phase 3 trial, timing of filing and acceptance of the Medidur NDA and EU marketing approval applications, if at all; ability to use data in a U.S. NDA from trials outside the U.S.; any exercise by Pfizer of its option with respect to the latanoprost product; our ability to develop Tethadur to successfully deliver large biologic molecules and develop products using it; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements, even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

 

Beverly Jedynak
O: 312-943-1123
M: 773-350-5793
bjedynak@janispr.com
Monday, December 28th, 2015 Uncategorized Comments Off on (PSDV) Plans Medidur™ EU Marketing Approval Application

(ROVI) Renews Patent License Agreement for Entertainment Discovery w/ Sony

Rovi Corporation (NASDAQ:ROVI) today announced that Rovi has renewed its worldwide license agreement with Sony Corporation. The multi-year agreement continues to provide Sony with a license to use Rovi’s entertainment discovery patent portfolio for its consumer electronics devices worldwide.

Rovi’s patents power entertainment discovery to help consumers navigate content across multiple screens and devices. With more than 5,000 issued or pending patents worldwide, Rovi’s extensive entertainment discovery patent portfolio covers a wide range of digital entertainment capabilities including interactive program guides, search and recommendations, and multi-screen experiences that power personalized entertainment.

About Rovi Corporation

Rovi is leading the way to a more personalized entertainment experience. The company’s pioneering guides, metadata and recommendations continue to drive program search and navigation on millions of devices across the globe. With a new generation of cloud-based discovery capabilities and emerging solutions for interactive advertising and audience analytics, Rovi is enabling premier brands worldwide to increase their reach, drive consumer satisfaction and create a better entertainment experience across multiple screens. Rovi holds over 5,000 issued or pending patents worldwide and is headquartered in Santa Clara, California. Discover more about Rovi at Rovicorp.com.

Forward-Looking Statements

All statements contained herein that are not statements of historical fact, including statements that use the words “will” or “is expected to,” or similar words that describe Rovi Corporation’s or its management’s future plans, objectives or goals, are “forward-looking statements” and are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Rovi Corporation to be materially different from the historical results and/or from any future results or outcomes expressed or implied by such forward-looking statements. Such factors are further addressed in Rovi Corporation’s most recent report on Form 10-Q for the period ended September 30, 2015, and such other documents as are filed with the Securities and Exchange Commission from time to time (available at www.sec.gov). Rovi Corporation assumes no obligation to update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, except as required by law.

 

Rovi Corporation
Stacey Hurwitz, +1 617-710-9171
Stacey.Hurwitz@rovicorp.com

Monday, December 28th, 2015 Uncategorized Comments Off on (ROVI) Renews Patent License Agreement for Entertainment Discovery w/ Sony

(ATNM) to Ring First Closing Bell of 2016 at the New York Stock Exchange

Company Commencing Transformational Year With Bell Ringing

NEW YORK, NY–(December 28, 2015) – Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium”), a biopharmaceutical company developing innovative drug candidates for the treatment of advanced cancers today announced that the Company will be ringing the closing bell at the New York Stock Exchange on January 4, 2016.

Sandesh Seth, Executive Chairman of Actinium, stated, “Actinium expects 2016 to be a transformational year where we will see our lead drug candidate, Iomab-B, begin a pivotal, Phase 3 clinical trial having just had its IND cleared and our cd33 targeting drug candidate, Actimab-A, begin a Phase 2 clinical trial. With many milestones ahead of us this year, we are very excited to begin the year by ringing the closing bell at the New York Stock Exchange.”

About Iomab-B

Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin’s disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

About Actimab-A

Actimab-A, Actinium’s most advanced alpha particle immunotherapy program, is currently in a single arm, multicenter trial Phase 1/2 trial for newly diagnosed AML patients over the age of 60. Actimab-A is being developed as a first-line therapy and it has attracted support from some of the leading experts at the most prestigious cancer treatment hospitals due to the potential of its safety and efficacy profile.

Actimab-A consists of the monoclonal antibody, lintuzumab, and the radioisotope, actinium-225. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. Lintuzumab is the humanized version of M195 and is a monoclonal antibody that targets CD33, which is abundantly found on myeloid leukemia cells. Both the alpha particle technology and lintuzumab were initially developed at Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Steve O’Loughlin
Senior Director, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com

Monday, December 28th, 2015 Uncategorized Comments Off on (ATNM) to Ring First Closing Bell of 2016 at the New York Stock Exchange

(AVID) Announces Groundbreaking Agreement With Sinclair to Transform the Newsroom

Innovative Commercial Approach and Unique Technology Deployment Model – Made Possible by Avid Everywhere – Helps Sinclair Cost-Effectively Keep Its News Operations at the Forefront of Technology for the Next Decade

BURLINGTON, Mass., Dec. 23, 2015  — Avid® (Nasdaq:AVID) today announced that Sinclair Broadcast Group, Inc., the largest television station operator and leading local news provider in the United States, has chosen to standardize on Avid’s MediaCentral Platform, the centerpiece of the Avid Everywhere vision, to transform content creation and distribution workflows in every one of its 64 local news producing stations. This agreement represents a record-setting contract for Avid where the Company will deliver advanced end-to-end newsroom production and content management solutions under a ten-year comprehensive agreement that uniquely addresses Sinclair’s business needs, and in the process, replaces legacy technology from other vendors.

“Moving to a common production platform across all of our news markets provides us the platform to create a content sharing news community across Sinclair increasing efficiency and productivity,” said Scott Livingston, Vice President of News, Sinclair Broadcast Group. “Having defined and more frequent technology upgrade cycles will enable us to keep our newsrooms current across the enterprise and allow us to respond to rapid changes like new digital distribution models in a more cost effective way.”

Operating efficiency is a major pressure point for media companies, as rapidly evolving technology and audience behavior make staying at the forefront of technology essential.  Sinclair expects to realize meaningful economic benefits through this agreement by standardizing on the Avid platform, driven by efficiencies from a standardized technology and operational footprint across all of its stations. This not only enables Sinclair to keep its newsroom technology consistent, continuously refreshed and on the leading edge across the enterprise, but also provides much greater flexibility in responding to industry changes and new business opportunities.

“Sinclair has always been at the forefront of industry-changing events and technological advances, and this agreement with Avid is another example of that,” added Delbert R. Parks, III, Senior Vice President and CTO of Sinclair Broadcast Group. “Avid’s forward thinking approach to technology acquisition, deployment and support delivers the agility and scalability we need to deliver a higher value product to all of our news markets.”

“The unique commercial model Avid is applying – along with the enterprise-wide platform approach – allows us to operate in a more cost effective and capital efficient way, yet remain technologically forward in a manner that makes sense for our business today and in the future,” said Christopher S. Ripley, CFO, Sinclair Broadcast Group.

“Our agreement with Sinclair is an outstanding example of how Avid Everywhere can help media organizations overcome the challenges of managing technology, staying competitive, and maximizing the value of content,” said Louis Hernandez, Jr., Chairman, President and CEO, Avid. “With our enterprise-wide thinking, innovative commercial approaches to support longer-term business models, and the industry’s leading open technology platform, Avid is uniquely positioned to help media organizations address the business challenges of today – and tomorrow. We are very proud to be working with Sinclair, who is well-known as a technology innovator in the media space. We couldn’t think of a better partner with whom to launch this groundbreaking managed services deployment model.”

Powered by the MediaCentral Platform, the next-generation IP-based workflow for Sinclair’s news producing stations will feature Avid’s Artist Suite, Storage Suite and Media Suite solutions with third-party and custom workflow integrations.  Avid Professional Services and Training teams will provide project and fleet management, commissioning, workflow consulting, and a comprehensive training curriculum. Avid’s Customer Care team will deliver a tailored 24/7 support program across the enterprise.

“We’re excited that the Avid Everywhere vision has led to the largest contract in our Company’s history. We expect this contract will have a material positive impact on our bookings for the fourth quarter and may lead to updated 2015 bookings guidance or pre-release in early January 2016,” said John W. Frederick, Executive Vice President, Chief Financial and Administrative Officer for Avid.

About Avid

Through Avid Everywhere™, Avid delivers the industry’s most open, innovative and comprehensive media platform connecting content creation with collaboration, asset protection, distribution and consumption. Media organizations and creative professionals use Avid solutions to create the most listened to, most watched and most loved media in the world—from the most prestigious and award-winning feature films, to the most popular television shows, news programs and televised sporting events, as well as a majority of today’s most celebrated music recordings and live concerts. Industry leading solutions include Pro Tools®, Media Composer®, ISIS®, Interplay®, ProSet and RealSet, Maestro, PlayMaker, and Sibelius®. For more information about Avid solutions and services, visit www.avid.com, connect with Avid on Facebook, Instagram, Twitter, YouTube, LinkedIn, or subscribe to Avid Blogs.

Cautionary Note Regarding Forward-Looking Statements

The information provided in this press release includes forward-looking statements that involve risks and uncertainties, including statements about our anticipated expectations, plans, earnings, bookings and operational results. Such statements are made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, without limitation, statements regarding the term of the Agreement, the total contract value of the Agreement, our earnings under the Agreement, our ongoing relationship with Sinclair and our future bookings. These forward-looking statements are based on current expectations as of the date of this press release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to the effect on our bookings, earnings, operations and financial performance, resulting from our ability to perform our obligations under the Agreement, a possible early termination of the Agreement, our ability to realize our expected earnings under the Agreement, our ability to provide innovative products and solutions, our ability to hire and retain competent and skilled technical personnel, quality issues our products may experience and competitive factors. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described in the filings made by our company with the SEC. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

© 2015 Avid Technology, Inc. All rights reserved. Avid, the Avid logo, Avid Everywhere, iNEWS, Interplay, ISIS, AirSpeed, Media Composer, Pro Tools, and Sibelius are trademarks or registered trademarks of Avid Technology, Inc. or its subsidiaries in the United States and/or other countries. The Interplay name is used with the permission of the Interplay Entertainment Corp. which bears no responsibility for Avid products. All other trademarks are the property of their respective owners. Product features, specifications, system requirements and availability are subject to change without notice.

PRESS CONTACT: 
Sara Griggs
Avid 
sara.griggs@avid.com 
310-907-6909
Wednesday, December 23rd, 2015 Uncategorized Comments Off on (AVID) Announces Groundbreaking Agreement With Sinclair to Transform the Newsroom

(LGCY) Declares Preferred Distributions

MIDLAND, Texas, Dec. 23, 2015  — Legacy Reserves LP (“Legacy”) (NASDAQ:LGCY) today announced that its general partner has declared a monthly cash distribution for both its 8% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Units and its 8% Series B Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Units of $0.166667 per unit payable on January 15, 2016 to unitholders of record on January 4, 2016.

About Legacy Reserves LP

Legacy Reserves LP is a master limited partnership headquartered in Midland, Texas, focused on the acquisition and development of oil and natural gas properties primarily located in the Permian Basin, East Texas, Rocky Mountain and Mid-Continent regions of the United States.  Additional information is available at www.LegacyLP.com.

Cautionary Statement Relevant to Forward-Looking Information

This press release contains forward-looking statements relating to our operations that are based on management’s current expectations, estimates and projections about its operations. Words such as “anticipates,” “expects,” “intends,” “plans,” “targets,” “projects,” “believes,” “seeks,” “schedules,” “estimated,” and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Among the important factors that could cause actual results to differ materially from those in the forward-looking statements are realized oil and natural gas prices, production volumes, lease operating expenses, general and administrative costs and finding and development costs; future operating results and the factors set forth under the heading “Risk Factors” in our annual and quarterly reports filed with the Securities and Exchange Commission.  Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. The reader should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Unless legally required, Legacy undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Withholding Information

This release is intended to be a qualified notice under Treasury Regulation Section 1.1446-4(b). Brokers and nominees should treat one hundred percent (100.0%) of Legacy’s distributions to foreign investors as being attributable to income that is effectively connected with a United States trade or business.  Accordingly, Legacy’s distributions to foreign investors are subject to federal income tax withholding at the highest applicable rate.

 

Legacy Reserves LP
Dan Westcott
Executive Vice President and Chief Financial Officer
432-689-5200
Wednesday, December 23rd, 2015 Uncategorized Comments Off on (LGCY) Declares Preferred Distributions